Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Hormones leptin and insulin work together to affect regulation of blood sugar levels, female fertility

New findings by UT Southwestern Medical Center researchers suggest that the hormones leptin and insulin work together in specific neurons in the hypothalamus region of the brain to affect both the regulation of blood sugar levels in the body and, surprisingly, female fertility.

12 Apr 2010

Independent management of diabetes a huge issue for teens

It is hard enough being a teenager − or the parent of a teenager − without also having to deal with type 1 diabetes. Keeping good control can be a problem when the responsibility for administering insulin and checking blood glucose levels passes from parent to child.

9 Apr 2010

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

Generex Biotechnology, Seaside 88 close first tranche of 2 million shares for gross proceeds of $945,180

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into a common stock purchase agreement with Seaside 88, LP, a private investment limited partnership. Seaside has committed to purchase up to 49,455,130 shares of Generex common stock.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Biopartners GmbH has announced that it has received EU marketing authorization from the European Commission for Ribavirin Biopartners 200mg film-coated tablets. The product is intended for the treatment of chronic hepatitis C infection as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b.

9 Apr 2010

Adherence to type 1 diabetes treatment lags if parents don't monitor

Teenagers and "tweenagers" with type 1 diabetes have more trouble sticking to their treatment plan - thus raising their risk of blindness, kidney failure and heart disease - if their parents become increasingly lax about monitoring the child's treatment, or if the mother-child relationship is poor.

8 Apr 2010

HeartWare's ADVANCE bridge-to-transplant clinical trial: FDA approves additional enrollment under CAP

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration has approved an IDE Supplement that allows HeartWare to enroll up to an additional 54 patients in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution (with Flavor Packs), the generic version of Braintree Laboratories' NuLytely® laxative.

8 Apr 2010

Updates from Phase I/IIa clinical trial of DIABECELL treatment in insulin-dependent diabetics

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today provided a penultimate update regarding the three-year follow up of its Phase I/IIa clinical trial in Russia of its DIABECELL® treatment in insulin-dependent diabetics.

7 Apr 2010

Jazzercise, Back in the Swing USA partner to promote breast cancer survivorship programs

Jazzercise, the world's leading dance fitness program, is proud to announce its partnership with Back in the Swing USA®, a grassroots nonprofit organization exclusively dedicated to providing awareness, access and financial support for breast cancer survivorship programs and academic medical research in the field of breast cancer survivorship.

7 Apr 2010

Gerresheimer AG sets up new sales office in Moscow

Gerresheimer AG has set up a sales office in Moscow. The new representation centre will intensify the Group's business in pharmaceutical primary packaging and drug-delivery systems. "This is a strategically important step to further develop the fast-growing pharma & healthcare markets of Russia and neighboring regions," says Gerresheimer CEO Dr. Axel Herberg.

7 Apr 2010

Obstacles in urban setting limits physical activity and promotes unhealthy food consumption

The conditions of urban environments have been linked to an escalation of noncommunicable diseases such as Type II diabetes, obesity, hypertension, and cardiovascular disease. These diseases are preventable and manageable through exercise, which is why the International Sports Sciences Association (ISSA) is dedicated to stemming the tide of poor health and physical decline by providing distance fitness education to health and fitness professionals, as well as other interested individuals.

7 Apr 2010

GE Capital, Healthcare Financial Services supports CCS Medical with $35M revolving line of credit

GE Capital, Healthcare Financial Services today announced it has provided a $35 million revolving line of credit to CCS Medical, Inc. The loan will be used to refinance existing debt, provide working capital and support growth initiatives following CCS Medical's exit from Chapter 11 bankruptcy protection on March 31, 2010.

7 Apr 2010

OICR invests $415,000 to develop radiolabelled insulin probe for early detection of breast cancer

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research today announced an investment of $415,000 towards the development of a radiolabelled insulin probe for the early detection of breast cancer.

6 Apr 2010

Wounded warriors learn skills to cope with post-traumatic stress disorder

Wounded Warrior Project and the National Ability Center of Park City, Utah have partnered for a fourth year to host 15 wounded warriors from April 6-10 as part of WWP's Project Odyssey program.

6 Apr 2010

TachoSil blood-clotting patch receives FDA approval for cardiovascular surgery

The U.S. Food and Drug Administration today approved TachoSil, the first absorbable fibrin sealant patch for use in cardiovascular surgery to prevent mild and moderate bleeding from small blood vessels, when standard surgical techniques are ineffective or impractical.

6 Apr 2010

Insulin News and Research

Further Reading

Hormones leptin and insulin work together to affect regulation of blood sugar levels, female fertility

Independent management of diabetes a huge issue for teens

"Nanovaccine" reverses diabetes

Generex Biotechnology, Seaside 88 close first tranche of 2 million shares for gross proceeds of $945,180

Nanotechnology-based vaccine cures mice with type 1 diabetes

Sanofi-Aventis acquires exclusive global rights to CureDM's Pancreate

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Adherence to type 1 diabetes treatment lags if parents don't monitor

HeartWare's ADVANCE bridge-to-transplant clinical trial: FDA approves additional enrollment under CAP

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

Updates from Phase I/IIa clinical trial of DIABECELL treatment in insulin-dependent diabetics

Jazzercise, Back in the Swing USA partner to promote breast cancer survivorship programs

Gerresheimer AG sets up new sales office in Moscow

Obstacles in urban setting limits physical activity and promotes unhealthy food consumption

GE Capital, Healthcare Financial Services supports CCS Medical with $35M revolving line of credit

OICR invests $415,000 to develop radiolabelled insulin probe for early detection of breast cancer

Wounded warriors learn skills to cope with post-traumatic stress disorder

TachoSil blood-clotting patch receives FDA approval for cardiovascular surgery

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News